Liability risks emerge as an obstacle in Europe’s COVID-19 vaccine negotiations: Reuters

By | August 26, 2020

With all eyes on the hunt for COVID-19 vaccines, Europe’s supply negotiations with drugmakers have hit snags over potential liability for side effects, Reuters reports

While some companies are in “advanced discussions” to supply tens or hundreds of millions of doses to European countries, only AstraZeneca has completed an agreement—for 400 million doses.

That deal provides AstraZeneca some protection, according to the news service. It “foresees that liabilities and financial costs are shared among the parties,” Belgium’s medicines agency told Reuters. AstraZeneca has agreed to provide doses at no profit during the pandemic.

Fierce Webinar

Leveraging Innovative Technologies, Best Practices and Strategies to Accelerate Biologics Development and Commercialization

Learn practical implementation of innovative technologies and solutions such as multi-attribute method, modernized cell line development workflow using high-yield cell lines and automated systems, next generation purification resins. The webinar will also showcase best practices and strategies such as phase appropriate quality systems, and integrated drug substance – drug product solutions that leverage standardized technology platforms.

Meanwhile, Johnson & Johnson, Sanofi and GSK, CureVac and Moderna are in “advanced” discussions to supply doses if their candidates succeed. But those deals haven’t yet been finalized, and liability risks could play into the talks. 

RELATED: Busy AstraZeneca inks yet another big COVID-19 vaccine deal, this time with EU 

In the U.S., the government assumes liability for vaccine side effects, an approach aimed at ensuring widespread vaccination, Reuters reports. But in Europe, laws place liability for side effects on drugmakers in most cases. Amid the pandemic, the EU has sought to reduce that liability to encourage faster vaccine research, according to the news service. 

So far, liability issues have played into the EU’s negotiations with U.S. pharma giants Johnson & Johnson and Pfizer, according to the report. 

RELATED: Europe’s COVID-19 vaccine negotiations hit snags with 3 drugmakers: Reuters 

Aside from the legal concerns, EU negotiations previously hit snags over the timing of payments and price, Reuters reported last month.

Read more on

FiercePharma: Pharma